Company Description
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States.
The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.
It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome.
The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
| Country | United States |
| Founded | 2014 |
| IPO Date | May 5, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 40 |
| CEO | Dr. Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir |
Contact Details
Address: 441 Ninth Avenue, 14th Floor New York, New York 10001 United States | |
| Phone | 212-776-4381 |
| Website | ovidrx.com |
Stock Details
| Ticker Symbol | OVID |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001636651 |
| CUSIP Number | 690469101 |
| ISIN Number | US6904691010 |
| Employer ID | 46-5270895 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir | President, Chief Executive Officer and Chairman |
| Jeffrey A. Rona | Principal Financial Officer, Principal Accounting Officer and Chief Business and Financial Officer |
| Jason Tardio M.B.A. | Chief Operating Officer |
| Lora Pike | Senior Director of Investor Relations and Public Relations |
| Thomas Michael Perone J.D., M.B.A. | General Counsel |
| Simon D. Kelner | Chief Human Resources Officer |
| Dr. Dirk Haasner | Senior Vice President of Global Manufacturing and CMC QA |
| Dr. Todd F. Baumgartner M.D., M.P.H. | Senior Vice President of Regulatory Affairs |
| Dr. Julia Tsai Ph.D. | Senior Vice President of Clinical Development |
| Meg Alexander | Chief Strategy Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 1, 2024 | 8-K | Current Report |
| Jun 28, 2024 | 8-K | Current Report |
| Jun 17, 2024 | 8-K | Current Report |
| Jun 7, 2024 | 8-K | Current Report |
| May 14, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 14, 2024 | 10-Q | Quarterly Report |
| May 14, 2024 | 8-K | Current Report |
| Apr 24, 2024 | ARS | Filing |
| Apr 24, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 24, 2024 | DEF 14A | Other definitive proxy statements |